Patent application number | Description | Published |
20090099185 | P38 Map Kinase Inhibitors - Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: | 04-16-2009 |
20090203711 | Inhibitors of P38 Map Kinase - Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: | 08-13-2009 |
20100010057 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE - Compounds of formula (I) are inhibitors of P13 kinase activity, and useful in treatment of, inter alia, autoimmune, inflammatory and proliferative diseases: wherein: s is 0 or 1; U is hydrogen or halogen; X is —(C═O), an optionally substituted divalent phenylene, pyridinylene, pyrimidinylene, or pyrazinylene radical, or a bond; P is optionally substituted C | 01-14-2010 |
20130197042 | HDAC INHIBITORS - Compounds of formula (I) inhibit HDAC activity: | 08-01-2013 |
Patent application number | Description | Published |
20090131461 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity - Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y | 05-21-2009 |
20120149736 | ENZYME INHIBITORS - Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH— Or —CH | 06-14-2012 |
20130303576 | ENZYME INHIBITORS - Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH—Or —CH | 11-14-2013 |
20140010762 | IMAGING AGENTS - An imaging agent for cells which produces an intracellular imaging signal proportional to the amount of hCE-1 in the cells independently of the amount of hCE-2 and/or hCE-3 in the cells, said imaging agent being a covalent conjugate of (a) an imaging agent and (b) an alpha mono- or di-substituted amino acid ester, wherein (a) is directly linked to (b), or (a) is indirectly linked to (b) by a linker radical, and wherein said direct or indirect linkage is via the amino group of (b), and wherein the amino group is not directly linked to a carbonyl group, and wherein the said alpha mono- or di-substituted amino acid ester part is selectively hydrolysable to the corresponding carboxylic acid part by the intracellular carboxylesterase enzyme hCE-1 relative to the intracellular enzymes hCE-2 or hCE-3. | 01-09-2014 |
20140088159 | ENZYME AND RECEPTOR MODULATION - Covalent conjugates of an α,α-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the α,α-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells. | 03-27-2014 |
20140155439 | ENZYME INHIBITORS - Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH— Or —CH | 06-05-2014 |
20140163042 | ENZYME INHIBITORS - Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R | 06-12-2014 |
20140323531 | HDAC INHIBITORS - Compounds of formula (I) inhibit HDAC activity: | 10-30-2014 |
20150246883 | TERT-BUTYL N-[2-ETHYL]-L-ALANINATE OR A SALT, HYDRATE OR SOLVATE THEREOF - The present invention provides a compound which is: tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alaninate or a salt, hydrate or solvate thereof. The present invention also provides a pharmaceutical composition comprising the compound together with one or more pharmaceutically acceptable carriers and/or excipients. The compound and composition are useful for inhibiting the activity of a p38 MAP kinase enzyme. As such they may be used in the treatment of a autoimmune or inflammatory disease, or a cell proliferative disease. In addition, the invention provides an acid produced by hydrolysis of the ester group of the compound of the invention. The acid is N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl)-L-alanine. | 09-03-2015 |
Patent application number | Description | Published |
20110048972 | MULTI-ANALYTE TEST STRIP WITH SHARED COUNTER/REFERENCE ELECTRODE AND INLINE ELECTRODE CONFIGURATION - A multi-analyte test strip includes a first insulating layer and an electrically conductive layer disposed on the first insulating layer. The electrically conductive layer has a first working electrode with a first analyte contact pad, a shared counter/reference electrode with a counter/reference electrode contact pad, and a second working electrode with a second analyte contact pad. The multi-analyte test strip also includes a second insulating layer disposed above the first insulating layer and a patterned spacer layer positioned between the first insulating layer and the first electrically conductive layer with the patterned spacer layer defining a bodily fluid sample-receiving chamber that overlies the first working electrode, the shared counter/reference electrode and the second working electrode. The multi-analyte test strip further includes a mediator reagent layer disposed over the first working electrode, the shared counter/reference electrode and the second working electrode; a first analyte reagent layer disposed over the first working electrode and mediator reagent layer; and a second analyte reagent layer disposed over the second working electrode and mediator reagent layer. Furthermore, the first analyte electrode, shared counter/reference electrode and second analyte electrode of the multi-analyte test strip are disposed on the first insulating layer in a planar inline configuration. | 03-03-2011 |
20110144915 | FILL SUFFICIENCY METHOD AND SYSTEM - Described and illustrated herein are one exemplary method and a measurement system having a meter and a test strip. The test strip has a first working electrode, reference electrode and second working electrode. In this method, acceptable fill data from known first current and known second current are used to predict an estimated second current at proximate the second time period (for a given batch of test strips) during the test sequence. The estimated second current at proximate the second time interval is then compared with a measured actual second current at proximate the second time interval during an actual test to determine if the measured actual second current is substantially equal to or within an acceptable percent deviation from the estimated second current so as to determine sufficient volume of a physiological fluid sample in the test strip. | 06-16-2011 |
20120312699 | DIFFERENTIABLE ANALYTICAL TEST STRIP AND TEST METER COMBINATION - An analytical test strip and test meter combination for use in the determination of an analyte in a bodily fluid sample includes an analytical test strip and a test meter, and a method for determination thereof. The analytical test strip has an electrode, a first electrical contact pad in electrical communication with the electrode and configured to communicate an electrical response of the electrode to the test meter; and a second electrical contact pad in electrical communication with the electrode and configured to communicate an electrical response of the electrode to the test meter should the test meter be in electrical communication with the second electrical contact pad. In addition, the second electrical contact pad has electrical continuity with the first electrical contact pad and the first and second electrical contact pads are disposed in either of first and second predetermined spatial relationships to one another. | 12-13-2012 |
20150068920 | FILL SUFFICIENCY METHOD AND SYSTEM - Described and illustrated herein are one exemplary method and a measurement system having a meter and a test strip. The test strip has a first working electrode, reference electrode and second working electrode. In this method, acceptable fill data from known first current and known second current are used to predict an estimated second current at proximate the second time period (for a given batch of test strips) during the test sequence. The estimated second current at proximate the second time interval is then compared with a measured actual second current at proximate the second time interval during an actual test to determine if the measured actual second current is substantially equal to or within an acceptable percent deviation from the estimated second current so as to determine sufficient volume of a physiological fluid sample in the test strip. | 03-12-2015 |
Patent application number | Description | Published |
20110094526 | BIODEGRADABLE COMPOSITES - The present invention concerns a biodegradable cigarette filter tow comprising composite filaments of cellulose and cellulose acetate, and a process for making such a filter tow comprising providing a solution dope comprising a blend of cellulose and cellulose acetate in an ionic liquid or in N-methylmorphilone-N-oxide (NMMO), and spinning casting the blend into a protic solvent to generate fibres or films, and converting the fibres or films into cigarette filter tow. The invention also concerns cigarette filters and cigarettes made from such a filter tow. | 04-28-2011 |
20120199147 | BIODEGRADABLE COMPOSITES - The present invention concerns a biodegradable cigarette filter tow comprising composite filaments of cellulose and cellulose acetate, and a process for making such a filter tow comprising providing a solution dope comprising a blend of cellulose and cellulose acetate in an ionic liquid or in N-methylmorphilone-N-oxide (NMMO), and spinning casting the blend into a protic solvent to generate fibres or films, and converting the fibres or films into cigarette filter tow. The invention also concerns cigarette filters and cigarettes made from such a filter tow. | 08-09-2012 |
20120202398 | BIODEGRADABLE FIBRE AND ITS PROCESS OF MANUFACTURE - The present invention concerns a biodegradable fibre comprising composite filaments of cellulose and cellulose acetate, and a process for making such a fibre comprising providing a solution dope comprising a blend of cellulose and cellulose acetate in an ionic liquid or in N-methylmorphilone-N-oxide (NMMO), and spinning casting the blend into a protic solvent to generate fibres. The invention also concerns materials made from such a fibre, and garments or soft furnishings made from such a material. | 08-09-2012 |
20130247926 | BIODEGRADABLE COMPOSITES - The present invention concerns a biodegradable cigarette filter tow comprising composite filaments of cellulose and cellulose acetate, wherein the composite filaments are entangled or wherein the two further comprises one or more further thermoplastic materials or wherein the weight ration of cellulose to cellulose acetate in the tow is from 10:90 to 90:10, and a process for making such a filter tow comprising providing a solution dope comprising a blend of cellulose and cellulose acetate in an ionic liquid or in N-methylmorphilone-N-oxide (NMMO), and spinning casting the blend into a protic solvent to generate fibres or films, and converting the fibres or films into cigarette filter tow. The invention also concerns cigarette filters and cigarettes made from such a filter tow. | 09-26-2013 |